Categorized | Stock Profiles

ISCO (International Stem Cell Corp.)

Share Button

isco logoInternational Stem Cell Corp. (ISCO) is a California based biotechnology company with over 200 patents, applications, and licenses focusing on the research and commercialization of biomedical, therapeutic, and cosmeceutical products.

Highlighted as one of America’s Fastest Growing Biotechnology Company, ISCO aims to develop treatments related to the brain, eye, and liver through a new proprietary technology, known as parthenogenesis, which provides several advantages over stem cell technologies. In brief, parthenogenesis is simply defined as a form of asexual reproduction in which the development and growth of embryos occurs without the need of fertilization. ISCO has chosen this form of development as research has observed this method expresses fewer parental histocompatibility antigens (a reduction in non-compatible tissues), a reduced risk of immune rejection and use of immune-supressing drugs, and offers the potential to treat genetic diseases for hundreds of millions of individuals.

Currently, the company has used its proprietary technology to Develop a Treatment for Parkinson’s Disease, a nervous system disorder that affects the body movement of an estimated one million Americans each year. After receiving U.S. Food and Drug Administration Clearance and Approval by the European Union, ISCO is moving forward with a pre-clinical program  to study the new opportunity for treatment of the disease. In doing so, the company has begun with  a pre-clinical study, with assistance by Tulane University and Duke University, of a new therapeutic stroke program and has successfully completed manufacturing of the First Cell Bank of clinical grade human neural stem cells.  Attention for this new treatment for Parkinson’s disease has received high levels of curiosity and interest by many that the company even received a request to present their studies and findings at the one of the world’s largest scientific and medical conferences by the Society for Neuroscience, the world’s largest organization of scientists and clinicians devoted to understand the brain and nervous system, for Advances in Stem Cell Research.  Additionally, the company was also a presenter at the Biotech Showcase, one of the industry’s largest annual healthcare investor conferences, at San FrancISCO, California.

Furthermore, the company additionally operates under two wholly-owned subsidiaries who collectively generated revenues of $6.1 million in the fiscal year of 2013.


Symbol: ISCO [ Current PPS: $0.0629 Outstanding Shares: 240.7M Float: 154M – a/o February 3, 2015 ]

isco chart





  • Many current stem cell lines can never be used to develop commercial therapeutic products because they do not meet the U.S. Food and Drug Administration’s ethical and quality standards.
  • Cell therapy has been proven clinically but is limited due to the availability of safe immune-matched human cells of tissue.
  • According to the Parkinson’s Disease Foundation, approximately 7 – 10 million people worldwide live with the disease.
  • Approximately 1 million Americans live with Parkinson’s disease, more than the combined total of people diagnosed with Lou Gehrig’s disease, multiple sclerosis, and muscular dystrophy.
  • Parkinson’s Disease has direct and indirect costs estimating $25 billion.
  • Market sales of the Parkinson’s Disease Drug Market will total $2.6 billion in 2020.
  • The Global Stem Cell Therapy Market is forecasted to increase at a compound annual growth rate of 39.5% from 2015 to 2020 and will total $330 million by 2020.
  • The study of human stem cells yields information about complex events that occur during human development.


Recent News


Get Updates on ISCO by Opting In to our Free 100% E-mail Newsletter!

This post was written by:

- who has written 2169 posts on StockRockandRoll.

Contact the author

Comments are closed.

© 2021 MJ Capital, LLC | All rights reserved